PCI Biotech is initiating a scientific collaboration with Bavarian Nordic to boost their cancer treatment technology.
Oslo Cancer Cluster member PCI Biotech has announced that it is initiating a preclinical research collaboration with Bavarian Nordic, a clinical stage biopharmaceutical corporation focused on developing state-of-the-art cancer immunotherapies and vaccines for infectious diseases.
The two collaborators will be exploring synergies between their two technologies to further enhance the effect of treatments of cancer and infectious diseases.
In brief, the collaborators will evaluate technology compatibility and synergy based on in vivo studies. The companies will evaluate results achieved from this research collaboration and then explore the potential for a further partnership.
CEO of PCI Biotech Per Walday says this regarding this fresh collaboration:
— I’m very pleased to announce another research agreement with a key player within the field of immunotherapies, which is the second collaboration initiated this year. We believe that the PCI technology has the potential to play a role in the realization of several new therapeutic treatments, and we look forward to exploring synergies with Bavarian Nordic’s unique and innovative technologies